PACS1 and Neurodevelopmental delay: The treatment of the PACS1 syndrome mice with antisense oligonucleotides targeting the PACS1R203W variant could restore the neuronal structure or communication suggesting that PACS1-NDD may be treated with targeted therapies [18].